Expedition Therapeutics
Clinical-stage biotech advancing EXPD-101, a once-daily oral DPP1 inhibitor licensed from Fosun Pharma, for COPD and other neutrophil-driven diseases, with a China-to-global in-licensing model.
Headquarters
San Francisco, USA
Year Founded
2024
Founders
Yi Larson (CEO)
Country
United States
Financial Information
Funding Stage
Series B
Recent Funding
$280M
Funding By
Sofinnova Investments, Novo Holdings, General Atlantic, Forbion, Venrock
Core Technology
Oral once-daily DPP1 inhibitor (neutrophil serine protease blockade)
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA Clinical
- Clinical Trial Registration: Phase 2 COPD (EXPD-101)
- Patents / IP Status: Licensed (ex-China rights from Fosun Pharma)
Partnerships
Pharma Collaborations
Fosun Pharma / S-Infinity Pharmaceuticals
Academic / Hospital Tie-ups
University of Dundee, University of Barcelona, University of Manchester, UAB
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
First-in-class DPP1 COPD program with rapid China-to-global clinical translation